Conversely, in colorectal cancer and melanoma, elevated GBP1 predicts favorable outcomes, linked to reduced proliferation or enhanced immune surveillance, detectable in tissue biopsies, peripheral blood, or circulating tumor cells via enzyme-linked immunosorbent assay (ELISA), mass spectrometry, or immune profiling [23,24]. Here, GBP1 is linked to melanoma.